newsfilter
← Latest News
GlobeNewswire·

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One's portfolio of targeted therapies